Works matching IS 08876924 AND DT 2012 AND VI 26 AND IP 2

Results: 30

Plasmin inhibitor reduces T-cell lymphoid tumor growth by suppressing matrix metalloproteinase-9-dependent CD11b(+)/F4/80(+) myeloid cell recruitment.

Published in:

2012

By:

Ishihara M;
Nishida C;
Tashiro Y;
Gritli I;
Rosenkvist J;
Koizumi M;
Okaji Y;
Yamamoto R;
Yagita H;
Okumura K;
Nishikori M;
Wanaka K;
Tsuda Y;
Okada Y;
Nakauchi H;
Heissig B;
Hattori K

Publication type:

Journal Article

Absence of IL-12R[beta]2 in CD33(+)CD38(+) pediatric acute myeloid leukemia cells favours progression in NOD/SCID/IL2R[gamma]C-deficient mice.

Published in:

2012

By:

Ferretti E;
Montagna D;
Di Carlo E;
Cocco C;
Ribatti D;
Ognio E;
Sorrentino C;
Lisini D;
Bertaina A;
Locatelli F;
Pistoia V;
Airoldi I

Publication type:

Journal Article

Constitutive activation of STAT3 in Sézary syndrome is independent of SHP-1.

Published in:

2012

By:

McKenzie RC;
Jones CL;
Tosi I;
Caesar JA;
Whittaker SJ;
Mitchell TJ

Publication type:

Journal Article

MRK003, a γ-secretase inhibitor exhibits promising in vitro pre-clinical activity in multiple myeloma and non-Hodgkin's lymphoma.

Published in:

2012

By:

Ramakrishnan V;
Ansell S;
Haug J;
Grote D;
Kimlinger T;
Stenson M;
Timm M;
Wellik L;
Halling T;
Rajkumar SV;
Kumar S;
Ramakrishnan, V;
Ansell, S;
Haug, J;
Grote, D;
Kimlinger, T;
Stenson, M;
Timm, M;
Wellik, L;
Halling, T

Publication type:

journal article

Constitutive activation of STAT3 in Sézary syndrome is independent of SHP-1.

Published in:

Leukemia (08876924), 2012, v. 26, n. 2, p. 323, doi. 10.1038/leu.2011.198

By:

McKenzie, R C T;
Jones, C L;
Tosi, I;
Caesar, J A;
Whittaker, S J;
Mitchell, T J

Publication type:

Article

Risk factors for early death after high-dose cytosine arabinoside (HiDAC)-based chemotherapy for adult AML.

Published in:

2012

By:

van der Jagt, A;
Muirhead, J;
Seymour, J F;
Bradstock, K F;
Paul, E;
Wei, A

Publication type:

Letter

High Epstein-Barr virus-specific T-cell counts are associated with near-zero likelihood of acute myeloid leukemia relapse after hematopoietic cell transplantation.

Published in:

2012

By:

Hoegh-Petersen, M;
Sy, S;
Ugarte-Torres, A;
Williamson, T S;
Eliasziw, M;
Mansoor, A;
Liu, Y;
Liu, S;
Podgorny, P;
Khan, F;
Duggan, P R;
Stewart, D A;
Russell, J A;
Storek, J

Publication type:

Letter

Prognostic implications and molecular associations of NADH dehydrogenase subunit 4 (ND4) mutations in acute myeloid leukemia.

Published in:

Leukemia (08876924), 2012, v. 26, n. 2, p. 289, doi. 10.1038/leu.2011.200

By:

Damm, F;
Bunke, T;
Thol, F;
Markus, B;
Wagner, K;
Göhring, G;
Schlegelberger, B;
Heil, G;
Reuter, C W M;
Püllmann, K;
Schlenk, R F;
Döhner, K;
Heuser, M;
Krauter, J;
Döhner, H;
Ganser, A;
Morgan, M A

Publication type:

Article

ETV6-RUNX1-positive childhood acute lymphoblastic leukemia: improved outcome with contemporary therapy.

Published in:

Leukemia (08876924), 2012, v. 26, n. 2, p. 265, doi. 10.1038/leu.2011.227

By:

Bhojwani, D;
Pei, D;
Sandlund, J T;
Jeha, S;
Ribeiro, R C;
Rubnitz, J E;
Raimondi, S C;
Shurtleff, S;
Onciu, M;
Cheng, C;
Coustan-Smith, E;
Bowman, W P;
Howard, S C;
Metzger, M L;
Inaba, H;
Leung, W;
Evans, W E;
Campana, D;
Relling, M V;
Pui, C-H

Publication type:

Article

TG02, a novel oral multi-kinase inhibitor of CDKs, JAK2 and FLT3 with potent anti-leukemic properties.

Published in:

Leukemia (08876924), 2012, v. 26, n. 2, p. 236, doi. 10.1038/leu.2011.218

By:

Goh, K C;
Novotny-Diermayr, V;
Hart, S;
Ong, L C;
Loh, Y K;
Cheong, A;
Tan, Y C;
Hu, C;
Jayaraman, R;
William, A D;
Sun, E T;
Dymock, B W;
Ong, K H;
Ethirajulu, K;
Burrows, F;
Wood, J M

Publication type:

Article

Telomere shortening, clonal evolution and disease progression in myelodysplastic syndrome patients with 5q deletion treated with lenalidomide.

Published in:

2012

By:

Göhring, G;
Lange, K;
Hofmann, W;
Nielsen, K V;
Hellström-Lindberg, E;
Roy, L;
Morgan, M;
Kreipe, H;
Büsche, G;
Giagounidis, A;
Schlegelberger, B

Publication type:

Letter

A novel prognostic model in myeloma based on co-segregating adverse FISH lesions and the ISS: analysis of patients treated in the MRC Myeloma IX trial.

Published in:

Leukemia (08876924), 2012, v. 26, n. 2, p. 349, doi. 10.1038/leu.2011.204

By:

Boyd, K D;
Ross, F M;
Chiecchio, L;
Dagrada, G P;
Konn, Z J;
Tapper, W J;
Walker, B A;
Wardell, C P;
Gregory, W M;
Szubert, A J;
Bell, S E;
Child, J A;
Jackson, G H;
Davies, F E;
Morgan, G J

Publication type:

Article

Absence of IL-12Rβ2 in CD33+CD38+ pediatric acute myeloid leukemia cells favours progression in NOD/SCID/IL2RγC-deficient mice.

Published in:

Leukemia (08876924), 2012, v. 26, n. 2, p. 225, doi. 10.1038/leu.2011.213

By:

Ferretti, E;
Montagna, D;
Di Carlo, E;
Cocco, C;
Ribatti, D;
Ognio, E;
Sorrentino, C;
Lisini, D;
Bertaina, A;
Locatelli, F;
Pistoia, V;
Airoldi, I

Publication type:

Article

How to manage primary amyloidosis.

Published in:

Leukemia (08876924), 2012, v. 26, n. 2, p. 191, doi. 10.1038/leu.2011.219

By:

Gertz, M A

Publication type:

Article

Monoclonal antibody-based therapy as a new treatment strategy in multiple myeloma.

Published in:

Leukemia (08876924), 2012, v. 26, n. 2, p. 199, doi. 10.1038/leu.2011.214

By:

van de Donk, N W C J;
Kamps, S;
Mutis, T;
Lokhorst, H M

Publication type:

Article

T-cell immunotherapy with a chimeric receptor against CD38 is effective in eliminating myeloma cells.

Published in:

2012

By:

Mihara, K;
Bhattacharyya, J;
Kitanaka, A;
Yanagihara, K;
Kubo, T;
Takei, Y;
Asaoku, H;
Takihara, Y;
Kimura, A

Publication type:

Letter

Human allo-reactive CD4+ T cells as strong mediators of anti-tumor immunity in NOD/scid mice engrafted with human acute lymphoblastic leukemia.

Published in:

Leukemia (08876924), 2012, v. 26, n. 2, p. 312, doi. 10.1038/leu.2011.222

By:

Stevanović, S;
Griffioen, M;
Nijmeijer, B A;
van Schie, M L J;
Stumpf, A N;
Rutten, C E;
Willemze, R;
Falkenburg, J H F

Publication type:

Article

CpG methylation patterns and decitabine treatment response in acute myeloid leukemia cells and normal hematopoietic precursors.

Published in:

Leukemia (08876924), 2012, v. 26, n. 2, p. 244, doi. 10.1038/leu.2011.207

By:

Negrotto, S;
Ng, K P;
Jankowska, A M;
Bodo, J;
Gopalan, B;
Guinta, K;
Mulloy, J C;
Hsi, E;
Maciejewski, J;
Saunthararajah, Y

Publication type:

Article

Characterization of BMS-911543, a functionally selective small-molecule inhibitor of JAK2.

Published in:

Leukemia (08876924), 2012, v. 26, n. 2, p. 280, doi. 10.1038/leu.2011.292

By:

Purandare, A V;
McDevitt, T M;
Wan, H;
You, D;
Penhallow, B;
Han, X;
Vuppugalla, R;
Zhang, Y;
Ruepp, S U;
Trainor, G L;
Lombardo, L;
Pedicord, D;
Gottardis, M M;
Ross-Macdonald, P;
de Silva, H;
Hosbach, J;
Emanuel, S L;
Blat, Y;
Fitzpatrick, E;
Taylor, T L

Publication type:

Article

Survival of patients with clinically identified monoclonal B-cell lymphocytosis (MBL) relative to the age- and sex-matched general population.

Published in:

2012

By:

Shanafelt, T D;
Kay, N E;
Rabe, K G;
Call, T G;
Zent, C S;
Schwager, S M;
Leis, J F;
Jelinek, D F;
Slager, S L;
Hanson, C A

Publication type:

Letter

KIR2DS1 genotype predicts for complete cytogenetic response and survival in newly diagnosed chronic myeloid leukemia patients treated with imatinib.

Published in:

Leukemia (08876924), 2012, v. 26, n. 2, p. 296, doi. 10.1038/leu.2011.180

By:

Marin, D;
Gabriel, I H;
Ahmad, S;
Foroni, L;
Lavallade, H de;
Clark, R;
O'Brien, S;
Sergeant, R;
Hedgley, C;
Milojkovic, D;
Khorashad, J S;
Bua, M;
Alsuliman, A;
Khoder, A;
Stringaris, K;
Cooper, N;
Davis, J;
Goldman, J M;
Apperley, J F;
Rezvani, K

Publication type:

Article

The novel calicheamicin-conjugated CD22 antibody inotuzumab ozogamicin (CMC-544) effectively kills primary pediatric acute lymphoblastic leukemia cells.

Published in:

Leukemia (08876924), 2012, v. 26, n. 2, p. 255, doi. 10.1038/leu.2011.206

By:

de Vries, J F;
Zwaan, C M;
De Bie, M;
Voerman, J S A;
den Boer, M L;
van Dongen, J J M;
van der Velden, V H J

Publication type:

Article

Comparison of childhood leukemia initiating cell populations in NOD/SCID and NSG mice.

Published in:

2012

By:

Diamanti, P;
Cox, C V;
Blair, A

Publication type:

Letter

MRK003, a γ-secretase inhibitor exhibits promising in vitro pre-clinical activity in multiple myeloma and non-Hodgkin's lymphoma.

Published in:

Leukemia (08876924), 2012, v. 26, n. 2, p. 340, doi. 10.1038/leu.2011.192

By:

Ramakrishnan, V;
Ansell, S;
Haug, J;
Grote, D;
Kimlinger, T;
Stenson, M;
Timm, M;
Wellik, L;
Halling, T;
Rajkumar, S V;
Kumar, S

Publication type:

Article

C-terminal mutation of RUNX1 attenuates the DNA-damage repair response in hematopoietic stem cells.

Published in:

Leukemia (08876924), 2012, v. 26, n. 2, p. 303, doi. 10.1038/leu.2011.202

By:

Satoh, Y;
Matsumura, I;
Tanaka, H;
Harada, H;
Harada, Y;
Matsui, K;
Shibata, M;
Mizuki, M;
Kanakura, Y

Publication type:

Article

DNA methylation pattern is altered in childhood T-cell acute lymphoblastic leukemia patients as compared with normal thymic subsets: insights into CpG island methylator phenotype in T-ALL.

Published in:

2012

By:

Kraszewska, M D;
Dawidowska, M;
Larmonie, N S D;
Kosmalska, M;
Sędek, Ł;
Szczepaniak, M;
Grzeszczak, W;
Langerak, A W;
Szczepański, T;
Witt, M

Publication type:

Letter

Plasmin inhibitor reduces T-cell lymphoid tumor growth by suppressing matrix metalloproteinase-9-dependent CD11b+/F4/80+ myeloid cell recruitment.

Published in:

Leukemia (08876924), 2012, v. 26, n. 2, p. 332, doi. 10.1038/leu.2011.203

By:

Ishihara, M;
Nishida, C;
Tashiro, Y;
Gritli, I;
Rosenkvist, J;
Koizumi, M;
Okaji, Y;
Yamamoto, R;
Yagita, H;
Okumura, K;
Nishikori, M;
Wanaka, K;
Tsuda, Y;
Okada, Y;
Nakauchi, H;
Heissig, B;
Hattori, K

Publication type:

Article

Evolving treatment strategies for patients newly diagnosed with chronic myeloid leukemia: the role of second-generation BCR-ABL inhibitors as first-line therapy.

Published in:

Leukemia (08876924), 2012, v. 26, n. 2, p. 214, doi. 10.1038/leu.2011.217

By:

Shami, P J;
Deininger, M

Publication type:

Article

Low frequency of DNMT3A mutations in pediatric AML, and the identification of the OCI-AML3 cell line as an in vitro model.

Published in:

2012

By:

Hollink, I H I M;
Feng, Q;
Danen-van Oorschot, A A;
Arentsen-Peters, S T C J M;
Verboon, L J;
Zhang, P;
de Haas, V;
Reinhardt, D;
Creutzig, U;
Trka, J;
Pieters, R;
van den Heuvel-Eibrink, M M;
Wang, J;
Zwaan, C M

Publication type:

Letter

Endogenous knockdown of survivin improves chemotherapeutic response in ALL models.

Published in:

Leukemia (08876924), 2012, v. 26, n. 2, p. 271, doi. 10.1038/leu.2011.199

By:

Morrison, D J;
Hogan, L E;
Condos, G;
Bhatla, T;
Germino, N;
Moskowitz, N P;
Lee, L;
Bhojwani, D;
Horton, T M;
Belitskaya-Levy, I;
Greenberger, L M;
Horak, I D;
Grupp, S A;
Teachey, D T;
Raetz, E A;
Carroll, W L

Publication type:

Article

Works matching IS 08876924 AND DT 2012 AND VI 26 AND IP 2

Plasmin inhibitor reduces T-cell lymphoid tumor growth by suppressing matrix metalloproteinase-9-dependent CD11b(+)/F4/80(+) myeloid cell recruitment.

Absence of IL-12R[beta]2 in CD33(+)CD38(+) pediatric acute myeloid leukemia cells favours progression in NOD/SCID/IL2R[gamma]C-deficient mice.

Constitutive activation of STAT3 in Sézary syndrome is independent of SHP-1.

MRK003, a γ-secretase inhibitor exhibits promising in vitro pre-clinical activity in multiple myeloma and non-Hodgkin's lymphoma.

Constitutive activation of STAT3 in Sézary syndrome is independent of SHP-1.

Risk factors for early death after high-dose cytosine arabinoside (HiDAC)-based chemotherapy for adult AML.

High Epstein-Barr virus-specific T-cell counts are associated with near-zero likelihood of acute myeloid leukemia relapse after hematopoietic cell transplantation.

Prognostic implications and molecular associations of NADH dehydrogenase subunit 4 (ND4) mutations in acute myeloid leukemia.

ETV6-RUNX1-positive childhood acute lymphoblastic leukemia: improved outcome with contemporary therapy.

TG02, a novel oral multi-kinase inhibitor of CDKs, JAK2 and FLT3 with potent anti-leukemic properties.

Telomere shortening, clonal evolution and disease progression in myelodysplastic syndrome patients with 5q deletion treated with lenalidomide.

A novel prognostic model in myeloma based on co-segregating adverse FISH lesions and the ISS: analysis of patients treated in the MRC Myeloma IX trial.

Absence of IL-12Rβ2 in CD33<sup>+</sup>CD38<sup>+</sup> pediatric acute myeloid leukemia cells favours progression in NOD/SCID/IL2RγC-deficient mice.

How to manage primary amyloidosis.

Monoclonal antibody-based therapy as a new treatment strategy in multiple myeloma.

T-cell immunotherapy with a chimeric receptor against CD38 is effective in eliminating myeloma cells.

Human allo-reactive CD4+ T cells as strong mediators of anti-tumor immunity in NOD/scid mice engrafted with human acute lymphoblastic leukemia.

CpG methylation patterns and decitabine treatment response in acute myeloid leukemia cells and normal hematopoietic precursors.

Characterization of BMS-911543, a functionally selective small-molecule inhibitor of JAK2.

Survival of patients with clinically identified monoclonal B-cell lymphocytosis (MBL) relative to the age- and sex-matched general population.

KIR2DS1 genotype predicts for complete cytogenetic response and survival in newly diagnosed chronic myeloid leukemia patients treated with imatinib.

The novel calicheamicin-conjugated CD22 antibody inotuzumab ozogamicin (CMC-544) effectively kills primary pediatric acute lymphoblastic leukemia cells.

Comparison of childhood leukemia initiating cell populations in NOD/SCID and NSG mice.

MRK003, a γ-secretase inhibitor exhibits promising in vitro pre-clinical activity in multiple myeloma and non-Hodgkin's lymphoma.

C-terminal mutation of RUNX1 attenuates the DNA-damage repair response in hematopoietic stem cells.

DNA methylation pattern is altered in childhood T-cell acute lymphoblastic leukemia patients as compared with normal thymic subsets: insights into CpG island methylator phenotype in T-ALL.

Plasmin inhibitor reduces T-cell lymphoid tumor growth by suppressing matrix metalloproteinase-9-dependent CD11b<sup>+</sup>/F4/80<sup>+</sup> myeloid cell recruitment.

Evolving treatment strategies for patients newly diagnosed with chronic myeloid leukemia: the role of second-generation BCR-ABL inhibitors as first-line therapy.

Low frequency of DNMT3A mutations in pediatric AML, and the identification of the OCI-AML3 cell line as an in vitro model.

Endogenous knockdown of survivin improves chemotherapeutic response in ALL models.